NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

NRBODelisted Stock  USD 2.14  0.00  0.00%   
About 62% of Neurobo Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Neurobo Pharmaceuticals suggests that many traders are alarmed regarding Neurobo Pharmaceuticals' prospects. Neurobo Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Neurobo Pharmaceuticals. Many technical investors use Neurobo Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the completion of enrollment of Part 1 of its two-part, Phase 2a clinical trial evaluating the efficacy and safety, of DA-1241, a novel G-Protein-Coupled Receptor 119 agonist for the treatment of metabolic dysfunction-associated steatohepatitis . Approximately 49 patients with presumed MASH have been randomized into Part 1 with a 1

Read at finance.yahoo.com
Yahoo News
  

Neurobo Pharmaceuticals Fundamental Analysis

We analyze Neurobo Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurobo Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurobo Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Total Debt

Total Debt Comparative Analysis

Neurobo Pharmaceuticals is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Neurobo Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Neurobo Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Neurobo Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Neurobo Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Neurobo Pharmaceuticals Related Equities

KPRXKiora Pharmaceuticals   11.71   
0%
100.0%
ALLRAllarity Therapeutics   1.94   
0%
16.0%
VRAXVirax Biolabs   1.87   
0%
15.0%
SONNSonnet Biotherapeutics   1.32   
0%
11.0%
ATNF180 Life   1.27   
10.0%
0%
BDRXBiodexa Pharmaceticals   1.38   
11.0%
0%
ZURAZura Bio   1.67   
14.0%
0%
REVBRevelation Biosciences   2.44   
20.0%
0%
QNRXQuoin Pharmaceuticals   3.39   
28.0%
0%
PHIOPhio Pharmaceuticals   4.81   
41.0%
0%
CDIOCardio Diagnostics   7.02   
59.0%
0%
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Other Consideration for investing in Neurobo Stock

If you are still planning to invest in Neurobo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neurobo Pharmaceuticals' history and understand the potential risks before investing.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Stocks Directory
Find actively traded stocks across global markets
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes